ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -62.9% | +91.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -62.9% over three years. Forward estimates point to Revenue at +91.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $548.56M | $6.07 | Not rated | -10.9 | +135.75% |
Ovid Therapeutics Inc. NASDAQ:OVID | $447.94M | $2.40 | Not rated | -7.1 | +91.80% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $341.74M | $6.99 | Not rated | -2.7 | +20.82% |
InflaRx N.V. NASDAQ:IFRX | $278.38M | $1.89 | Not rated | -2.7 | -5.22% |
Sutro Biopharma, Inc. NASDAQ:STRO | $154.64M | $15.98 | Not rated | -0.0 | +2.95% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $68.00M | $1.08 | Not rated | -4.0 | -74.53% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $63.74M | $2.92 | Not rated | -2.5 | -66.67% |
Context Therapeutics Inc. NASDAQ:CNTX | $31.76M | $0.35 | Not rated | -1.5 | -39.21% |
Continue the stock analysis
Jump to another research area for this company.